Is STE a good stock to buy?
STERIS plc · end-of-day data as of Nov 13, 2026
- PT$279.75 +5.8%
- ConsensusBuy · 9
- MAs4 of 4
- MACD2.19
- Sector▲ +15.9%
- Earnings in82d
- P/E31.4x
- Support-5.2%
- Resistance+0.2%
- Off 52w high-1.9%
- Volume1.1x
- Bollingerupper half
- News0.00
- FCF yield+3.7%
- P/E vs sector-2.7%
- Trendsideways
- 52w range$195–$269
- ATR+2.6%
- Off ATH-1.9%
- P/E vs own+10.1%
- Insiders-$2.74M
- RSI76
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Steris a good stock to buy?
Steris is strong on 1 of the 5 questions about the business. The price is about usual: 31.4 times its earnings, near its 3-year median of 36.7 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage some edge
- Economics profitable
- Execution mixed
- Fragility sturdy
- Price about usual
STE sales growth revenue growth
+6%a year, for the last 3 yearsSteris' sales grew 6% a year for 3 years, to $5.94B in fiscal 2026.
STE analysts' forecast revenue estimates
+7%the sales they expect next fiscal year, on the lastAnalysts expect Steris' sales to grow 7% to $6.37B in fiscal 2027 (6 analysts).
STE peers
pretickt analysis+8%its sales in 12 months, on a year before
Steris' sales grew 8% in the 12 months to Sep 30, 2026, faster than Viatris (+4%), slower than Incyte (+25%), West Pharmaceutical Services (+13%) and Quest Diagnostics (+9%).
STE sales by business revenue by segment
52%of its sales from ProductProduct brought Steris 52% of its sales in fiscal 2026; Service 48%.
STE return on capital ROIC
pretickt analysis17%earned before tax on the money invested in itSteris earned 17% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Incyte 29%, West Pharmaceutical Services 28%, Quest Diagnostics 13% and Viatris 0%.
STE margin on each sale gross margin
45%left after making the productSteris kept 45% of each sale after making the product in the 12 months to Sep 30, 2026; its peers' median is 36%.
STE margin after costs profit margin
19%of sales left after running the businessSteris' operating margin was 19% in the 12 months to Sep 30, 2026, against 5% in fiscal 2023.
STE cash generated free cash flow
$937Mcash left after investing, last 12 monthsSteris generated $937M of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
STE earnings vs estimates
5 of 8quarters above the analysts' estimateSteris beat the analysts' profit estimate in 5 of its last 8 quarters, the latest on Nov 4, 2026.
STE insider selling
-$7.84Msold, net, by its executives in 12 monthsSteris' executives and directors sold a net $7.84M of shares in the 12 months to Nov 13, 2026; none bought.
STE number of employees
+1%more people in a yearSteris had 17,937 employees at the end of fiscal 2026, 1% more than a year before.
STE CEO pay
$11.51Mfor fiscal 2026, 75% of it in stock and optionsSteris paid its CEO $11.51M for fiscal 2026, 75% of it in stock and options.
STE financial health Altman Z-score
5.8Altman Z-score, safe above 3Steris' Altman Z-score is 5.8 (Nov 13, 2026), above 3, where the safe zone starts.
STE quality checks Piotroski score
8 of 9checks passedSteris passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio.
STE biggest customers
under 10%of sales from any one customerNo customer made 10% of Steris' sales in fiscal 2026.
STE in past recessions
pretickt analysis-3%its sales in the worst oneSteris' sales fell in 1 of the last 2 US recessions, by as much as 3% in fiscal 2010.
STE price vs profit P/E ratio
31.4×a year's earningsSteris' P/E ratio is 31.4 (Nov 13, 2026), near its 3-year median of 36.7.
STE price vs peers
pretickt analysis31.4×a year's earnings, against its peersInvestors pay 31.4 times Steris' earnings (Nov 13, 2026), more than for Quest Diagnostics (25.9), less than for Incyte (64.3) and West Pharmaceutical Services (46.7).
STE analysts' target price target
+6%to their average targetAnalysts' average price target for Steris is $280, 6% above the Nov 13, 2026 close of $264.32.
STE growth priced in fair value
pretickt analysis+11%a year, for ten years, to be worth the priceAt $264.32 a share, Steris' free cash flow must grow about 11% a year for ten years to be worth the price (Nov 13, 2026).
What is Steris' P/E ratio?
Steris' P/E ratio is 31.4 (Nov 13, 2026), near its 3-year median of 36.7. Investors pay 31.4 times Steris' earnings (Nov 13, 2026), more than for Quest Diagnostics (25.9), less than for Incyte (64.3) and West Pharmaceutical Services (46.7).
Is Steris profitable?
Steris' operating margin was 19% in the 12 months to Sep 30, 2026, against 5% in fiscal 2023. Steris generated $937M of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
Are insiders selling Steris stock?
Steris' executives and directors sold a net $7.84M of shares in the 12 months to Nov 13, 2026; none bought.
How does Steris make money?
Product brought Steris 52% of its sales in fiscal 2026; Service 48%.
How many employees does Steris have?
Steris had 17,937 employees at the end of fiscal 2026, 1% more than a year before.
Who are Steris' biggest customers?
No customer made 10% of Steris' sales in fiscal 2026.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.